Indications for: NOVOLOG


Adult Dosage:

For SC inj, CSII, or IV infusion: see full labeling. Onset 10–20mins, peak 1–3hrs, duration 3–5hrs.

Children Dosage:

<2yrs: not recommended. 2–4yrs: use SC inj only. ≥4yrs: may use SC inj or CSII: see full labeling. Onset 10–20mins, peak 1–3hrs, duration 3–5hrs.

NOVOLOG Contraindications:

During episodes of hypoglycemia.

NOVOLOG Warnings/Precautions:

Instruct patients on proper administration of insulin, check insulin label before each injection, and management of hypoglycemia. Do not reuse or share pens, cartridges between patients, even if the needle is changed (or needles and syringes when using vials). Do not inject into areas of lipodystrophy or localized cutaneous amyloidosis. Increased risk of hyperglycemia or hypoglycemia if changes in physical activity, meal patterns, renal or hepatic function, insulin regimen, administration site; and if acute illness occurs: monitor glucose more frequently and may need to adjust dose. Monitor potassium levels in patients at risk for hypokalemia (eg, concomitant K+-lowering or K+-sensitive drugs). Discontinue if hypersensitivity reactions occur. Hyperglycemia and ketoacidosis due to insulin pump device malfunction: see full labeling. Visual impairment. Renal or hepatic impairment. Pregnancy. Nursing mothers.

NOVOLOG Interactions:

Concomitant thiazolidinediones (TZDs) may cause fluid retention and heart failure; consider dose reduction or discontinue TZDs. Potentiated by oral antidiabetic agents, ACE inhibitors, ARBs, disopyramide, fibrates, fluoxetine, MAOIs, pentoxifylline, pramlintide, propoxyphene, salicylates, somatostatin analog, sulfonamide antibiotics. Antagonized by atypical antipsychotics, corticosteroids, isoniazid, niacin, danazol, diuretics, glucagon, thiazides, phenothiazines, sympathomimetics, somatropin, thyroid hormones, estrogens, progestogens, protease inhibitors. Variable effects with β-blockers, clonidine, lithium salts, alcohol, pentamidine. Concomitant β-blockers, clonidine, guanethidine, reserpine may blunt hypoglycemia. CSII: Do not mix with other insulins or diluent when pump is used.

Adverse Reactions:

Hypoglycemia, hypokalemia, local inj site reactions, lipodystrophy, rash, pruritus, edema, sodium retention, weight gain; hypersensitivity and allergic reactions.

Generic Drug Availability:


How Supplied:

Vials (10mL)—1; FlexPen (3mL prefilled syringe)—5; PenFill (3mL cartridges)—5; NovoPen Echo (inj device, uses PenFill cartridges)—1